6 results
The objectives of this open-label study are to evaluate the efficacy (GL-3 clearance), pharmacokinetics (PK), and safety parameters (including immunogenicity) for 2 alternative dose regimens of Fabrazyme (0.5 mg/kg every 2 weeks [q2w] and 1.0 mg/kg…
The primary objectives of this study are: * To characterize the effects of 150 mg and 450 mg of AT1001 administered 2 hours before administration of agalsidase on the safety and plasma pharmacokinetics of agalsidase in subjects with Fabry Disease*…
The aim of this study is to evaluate cardio-protective effects of xenon inhalation in humans and to identify enzymes contributing to cardio-protection influenced by xenon in patients scheduled for CABG surgery.
The aim of this study is to evaluate the immediate effect of xenon inhalation on cardiac performance in patients scheduled for CABG surgery in comparison with the effect induced by sevoflurane inhalation.
To evaluate the safety and efficacy of PRX-102 compared to agalsidase beta in Fabry disease patients with impaired renal function.
Primary Objective: To verify the main effect of TDCS on brain excitability and the interaction effects of BDNF genotype and APLM latency on this main effect. Secondary Objectives: Compare different prediction models for the main effect of TDCS in a…